CERVICAL ADENOCARCINOMA
Clinical trials for CERVICAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CERVICAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for CERVICAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can adding radiation boost the power of immunotherapy in advanced cervical cancer?
Disease control Recruiting nowThis trial is investigating whether adding radiation therapy to a standard combination of chemotherapy and two targeted drugs can improve outcomes for people with stage IVB cervical cancer. The study combines external beam radiation and internal brachytherapy with cisplatin, pacl…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Lymph node surgery may boost cervical cancer treatment
Disease control Recruiting nowThis study looks at whether surgically removing para-aortic lymph nodes before standard chemoradiation can improve disease-free survival in people with stage IIIC1 cervical cancer. About 510 participants will be randomly assigned to either standard treatment or surgery plus tailo…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New smart chemo targets tumors, spares healthy tissue
Disease control Recruiting nowThis early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while r…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Avacta Life Sciences Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Could a 3-Week radiation course beat the standard for cervical cancer?
Disease control Recruiting nowThis study compares a shorter, higher-dose radiation schedule (hypofractionated radiotherapy) to the standard longer course for women with locally advanced cervical cancer in Uganda. About 278 participants will receive either the shorter or standard radiation, plus chemotherapy a…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Uganda Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Virus therapy takes on cervical and endometrial cancer
Disease control Recruiting nowThis study tests a modified virus (KD01) that targets and kills cancer cells, given alone or with an immunotherapy drug (AK104). It includes 97 women with cervical or endometrial cancer, some of whom have not responded to standard treatments. The goal is to see if the virus is sa…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for rare cervical cancer: Triple-Drug trial launches
Disease control Recruiting nowThis study tests a combination of three drugs (IN10018, nab-paclitaxel, and cadonilimab) in 25 women with a rare, aggressive cervical cancer that has spread or returned. The goal is to see if this treatment can shrink tumors or slow the disease. Participants must have already tri…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug combo aims to stop cervical cancer recurrence in high-risk patients
Disease control Recruiting nowThis study tests whether adding the drug serplulimab to standard chemoradiotherapy after surgery can help prevent cervical cancer from returning in patients with multiple risk factors. About 134 women aged 18-65 with PD-L1 positive cervical cancer will be randomly assigned to rec…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC